MedWatch

Genmab beats expectations across the board

Analysts had not anticipated such a strong performance from the Danish biotech firm, which has surpassed second-quarter estimates for every accounting item imaginable.

Photo: Joost Melis / Genmab / PR

Genmab ended the second quarter of 2022 with considerable more money than at the end of same period last year, while beating every projection made by analysts prior to the Danish biotech company publishing its report on Wednesday.

After trading closed yesterday, Genmab could tell the world that it has generated DKK 3.2bn (USD 442.3m) in the months of April, May, and June, which brings the company’s bottom line up to DKK 1.9bn (USD 262.7m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs